YU16501A - 4-karboksiamido-2-supstituisani-1,2,3,4-tetrahidrohinolini kao inhibitori cetp - Google Patents
4-karboksiamido-2-supstituisani-1,2,3,4-tetrahidrohinolini kao inhibitori cetpInfo
- Publication number
- YU16501A YU16501A YU16501A YU16501A YU16501A YU 16501 A YU16501 A YU 16501A YU 16501 A YU16501 A YU 16501A YU 16501 A YU16501 A YU 16501A YU 16501 A YU16501 A YU 16501A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- tetrahydroquinolines
- carboxyamino
- substituted
- cetp inhibitors
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Inhibitori transfera proteina holesterilestraformule (I) njihovi prolekovi ili farmaceutski prihvatljiva so pomenutih jedinjenja ili pomenutih prolekova, farmaceutski preparati koji sadrže ove inhibitore i upotreba ovih jedinjenja za proizvodnju leka za lečenje bolesti na koje štetno utiče nizak nivo HDL-holesterola i/ili visok nivo LDL-holesterola i triglicerida, kao što su ateroskleroza i kardiovaskularna oboljenja, kod sisara.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10086098P | 1998-09-17 | 1998-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU16501A true YU16501A (sh) | 2004-05-12 |
Family
ID=22281914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU16501A YU16501A (sh) | 1998-09-17 | 1999-09-10 | 4-karboksiamido-2-supstituisani-1,2,3,4-tetrahidrohinolini kao inhibitori cetp |
Country Status (47)
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
US20080153761A1 (en) * | 1998-04-08 | 2008-06-26 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
US6984667B2 (en) * | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US20040230559A1 (en) * | 1999-08-09 | 2004-11-18 | Mark Newman | Information processing device and information processing method |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
HN2000000203A (es) | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
IL154348A0 (en) * | 2000-08-15 | 2003-09-17 | Pfizer Prod Inc | Therapeutic combination of a cetp inhibitor and atorvastatin |
EP1325914A4 (en) | 2000-09-14 | 2004-11-17 | Kaken Pharma Co Ltd | TETRAHYDROQUINOLINE COMPOUNDS |
DK1425270T3 (da) * | 2001-04-30 | 2006-07-03 | Pfizer Prod Inc | Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer |
JP2005500314A (ja) * | 2001-06-21 | 2005-01-06 | ファイザー・プロダクツ・インク | コレステロールエステル転送蛋白インヒビターの自己乳化性製剤 |
US20030170309A1 (en) * | 2001-06-22 | 2003-09-11 | Babcock Walter C. | Pharmaceutical compositions containing polymer and drug assemblies |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
ATE444060T1 (de) * | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
EP1401503B1 (en) * | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
IL158771A0 (en) | 2001-06-22 | 2004-05-12 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug |
GT200200170A (es) * | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
BR0215240A (pt) * | 2001-12-19 | 2004-10-26 | Atherogenics Inc | Derivados de calcona e seu uso no tratamento de doenças |
AU2002361811A1 (en) | 2001-12-19 | 2003-07-09 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
RU2004123637A (ru) * | 2002-02-01 | 2005-04-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
PL373914A1 (en) * | 2002-02-01 | 2005-09-19 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
CA2472028C (en) | 2002-02-01 | 2010-03-30 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
MXPA04007438A (es) * | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
RU2293078C2 (ru) | 2002-08-30 | 2007-02-10 | Джапан Тобакко Инк. | Соединения дибензиламина, фармацевтическая композиция и терапевтический или профилактический агент на их основе, способ лечения или профилактики гиперлипидемии или артериосклероза |
US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) * | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
JP2006508077A (ja) * | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのpgd2レセプタアンタゴニスト |
JP2006511486A (ja) * | 2002-10-21 | 2006-04-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Crth2拮抗剤としてのテトラヒドロキノリン誘導体 |
US20040181075A1 (en) * | 2002-12-19 | 2004-09-16 | Weingarten M. David | Process of making chalcone derivatives |
WO2004056358A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
AU2003286372A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
WO2004072042A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
WO2004072046A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
CA2519458A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
CN101036636A (zh) * | 2003-03-17 | 2007-09-19 | 日本烟草产业株式会社 | 提高s-[2-([[1-(2-乙基丁基)环己基]羰基]氨基)苯基]-2-甲基丙硫代酸酯口服生物利用度的方法 |
DK1603553T3 (da) | 2003-03-17 | 2012-01-30 | Japan Tobacco Inc | Farmaceutiske præparater af CETP-inhibitorer |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
MXPA05012900A (es) * | 2003-05-30 | 2006-02-22 | Ranbaxy Lab Ltd | Derivados de pirrol sustituidos. |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
CA2534371A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
MXPA06001417A (es) * | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
CN1886124A (zh) | 2003-09-26 | 2006-12-27 | 日本烟草产业株式会社 | 抑制残余脂蛋白产生的方法 |
JP2007507481A (ja) * | 2003-09-30 | 2007-03-29 | ファイザー・プロダクツ・インク | Cetp阻害薬及びその代謝産物 |
EP2098512A1 (en) * | 2003-10-08 | 2009-09-09 | Eli Lilly & Company | Compounds and methods for treating dyslipidemia |
WO2005046662A2 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
DE602005014955D1 (de) | 2004-03-26 | 2009-07-30 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
US7923043B2 (en) * | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
WO2006012093A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
WO2006004903A2 (en) * | 2004-06-28 | 2006-01-12 | Atherogenics, Inc. | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
CA2624601C (en) | 2004-10-06 | 2018-07-03 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
US7923573B2 (en) | 2004-10-27 | 2011-04-12 | Daiichi Sankyo Company, Limited | Benzene compound having 2 or more substituents |
CA2590533C (en) * | 2004-11-23 | 2010-09-07 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
WO2006082518A1 (en) | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
AU2006216713A1 (en) * | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
CA2627599A1 (en) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
TW200744583A (en) * | 2006-03-14 | 2007-12-16 | Ranbaxy Lab Ltd | Statin stabilizing dosage formulations |
UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
US20100029716A1 (en) * | 2006-04-10 | 2010-02-04 | Concert Pharmaceuticals, Inc. | Novel 1,2,3,4- tetrahydroquinoline derivatives |
BRPI0714361A2 (pt) * | 2006-07-14 | 2013-03-26 | Ranbaxy Lab Ltd | polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
AR065670A1 (es) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
CA2681628C (en) | 2007-03-16 | 2016-10-18 | Concert Pharmaceuticals, Inc. | Inhibitors of cholesterol ester transfer protein |
CN101679309B (zh) | 2007-04-13 | 2012-02-29 | 兴和株式会社 | 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物 |
JP4846769B2 (ja) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
CA2761853A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
MY184008A (en) | 2009-05-15 | 2021-03-17 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
US9176146B2 (en) * | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
US9050275B2 (en) * | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
WO2011061168A1 (en) | 2009-11-17 | 2011-05-26 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
MX2012009149A (es) | 2010-02-19 | 2012-09-28 | Boehringer Ingelheim Int | Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion. |
US20130072519A1 (en) | 2010-05-21 | 2013-03-21 | Edward Lee Conn | 2-phenyl benzoylamides |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
ES2648788T3 (es) | 2011-01-26 | 2018-01-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular |
US20130053404A1 (en) | 2011-02-17 | 2013-02-28 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
US20130345392A1 (en) | 2011-03-04 | 2013-12-26 | Pfizer Inc | Edn3-like peptides and uses thereof |
EP2760868B1 (en) | 2011-08-17 | 2018-04-25 | Boehringer Ingelheim International GmbH | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
AR087451A1 (es) * | 2011-08-17 | 2014-03-26 | Lilly Co Eli | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes |
WO2013080999A1 (ja) | 2011-11-29 | 2013-06-06 | 興和株式会社 | NPC1L1及び/又はLIPG mRNAの発現抑制剤並びに肥満症の予防及び/又は治療剤 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
TR201808541T4 (tr) | 2013-02-14 | 2018-07-23 | Novartis Ag | Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri. |
EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
CN105705167A (zh) | 2013-07-25 | 2016-06-22 | 诺华股份有限公司 | 合成的apelin多肽的生物缀合物 |
CN105612172A (zh) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状多肽 |
CA2953483C (en) | 2014-07-30 | 2023-04-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
PL3180314T3 (pl) * | 2014-08-12 | 2022-11-21 | Newamsterdam Pharma B.V. | Sposób wytwarzania syntetycznych związków pośrednich do wytwarzania pochodnych tetrahydrochinoliny |
BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
EP3911648A4 (en) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231402A (en) * | 1985-04-02 | 1993-07-27 | Telefunken Systemtechnik Gmbh | Method for detecting and classifying helicopters |
US5231102A (en) | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
IL93610A0 (en) * | 1989-03-08 | 1990-12-23 | Merck Sharp & Dohme | Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them |
US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
KR920014799A (ko) | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
US5288725A (en) | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US6170342B1 (en) * | 1997-05-19 | 2001-01-09 | Particle Science | Spiral sampler |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
DK1425270T3 (da) * | 2001-04-30 | 2006-07-03 | Pfizer Prod Inc | Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer |
-
1999
- 1999-09-07 US US09/391,152 patent/US6197786B1/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481401A patent/PA8481401A1/es unknown
- 1999-09-09 HN HN1999000154A patent/HN1999000154A/es unknown
- 1999-09-10 YU YU16501A patent/YU16501A/sh unknown
- 1999-09-10 CN CNB998110523A patent/CN1331858C/zh not_active Expired - Fee Related
- 1999-09-10 TW TW088115687A patent/TWI242007B/zh not_active IP Right Cessation
- 1999-09-10 BR BR9913810-7A patent/BR9913810A/pt not_active Application Discontinuation
- 1999-09-10 PT PT99940424T patent/PT1114031E/pt unknown
- 1999-09-10 PL PL99347099A patent/PL347099A1/xx not_active Application Discontinuation
- 1999-09-10 DK DK99940424T patent/DK1114031T3/da active
- 1999-09-10 HU HU0103506A patent/HUP0103506A3/hu unknown
- 1999-09-10 MY MYPI99003917A patent/MY130670A/en unknown
- 1999-09-10 NZ NZ509840A patent/NZ509840A/xx unknown
- 1999-09-10 AP APAP/P/2001/002101A patent/AP1346A/en active
- 1999-09-10 AU AU54401/99A patent/AU752566B2/en not_active Ceased
- 1999-09-10 CO CO99057642A patent/CO5370678A1/es not_active Application Discontinuation
- 1999-09-10 PE PE1999000921A patent/PE20001069A1/es not_active Application Discontinuation
- 1999-09-10 CZ CZ2001955A patent/CZ2001955A3/cs unknown
- 1999-09-10 GT GT199900150A patent/GT199900150A/es unknown
- 1999-09-10 AT AT99940424T patent/ATE297898T1/de not_active IP Right Cessation
- 1999-09-10 KR KR10-2001-7003402A patent/KR100428330B1/ko not_active IP Right Cessation
- 1999-09-10 SK SK354-2001A patent/SK3542001A3/sk unknown
- 1999-09-10 ID IDW20010622A patent/ID28026A/id unknown
- 1999-09-10 TR TR2001/00768T patent/TR200100768T2/xx unknown
- 1999-09-10 DE DE69925845T patent/DE69925845T2/de not_active Expired - Fee Related
- 1999-09-10 WO PCT/IB1999/001532 patent/WO2000017164A1/en active IP Right Grant
- 1999-09-10 JP JP2000574074A patent/JP3626685B2/ja not_active Expired - Fee Related
- 1999-09-10 EP EP99940424A patent/EP1114031B1/en not_active Expired - Lifetime
- 1999-09-10 GE GEAP19995805A patent/GEP20033051B/en unknown
- 1999-09-10 ES ES99940424T patent/ES2243069T3/es not_active Expired - Lifetime
- 1999-09-10 OA OA1200100061A patent/OA11650A/en unknown
- 1999-09-10 AR ARP990104555A patent/AR021481A1/es active IP Right Grant
- 1999-09-10 CA CA002344350A patent/CA2344350C/en not_active Expired - Fee Related
- 1999-09-10 EE EEP200100166A patent/EE200100166A/xx unknown
- 1999-09-10 IL IL14150599A patent/IL141505A0/xx not_active IP Right Cessation
- 1999-09-10 EA EA200100202A patent/EA004674B1/ru unknown
- 1999-09-13 TN TNTNSN99171A patent/TNSN99171A1/fr unknown
- 1999-09-13 DZ DZ990190A patent/DZ2890A1/xx active
- 1999-09-13 MA MA25765A patent/MA26688A1/fr unknown
- 1999-10-09 UA UA2001031790A patent/UA68390C2/uk unknown
-
2000
- 2000-09-10 CU CU20010050A patent/CU23082A3/es unknown
- 2000-10-10 US US09/685,380 patent/US6586448B1/en not_active Expired - Fee Related
-
2001
- 2001-02-14 CR CR6310A patent/CR6310A/es unknown
- 2001-02-19 IL IL141505A patent/IL141505A/en unknown
- 2001-02-23 IS IS5859A patent/IS5859A/is unknown
- 2001-03-16 HR HR20010201A patent/HRP20010201A2/hr not_active Application Discontinuation
- 2001-03-16 NO NO20011350A patent/NO318830B1/no unknown
- 2001-04-10 BG BG105428A patent/BG65125B1/bg unknown
-
2002
- 2002-02-26 HK HK02101439.5A patent/HK1040243A1/zh unknown
-
2003
- 2003-06-27 US US10/607,640 patent/US6906082B2/en not_active Expired - Fee Related
-
2004
- 2004-08-18 JP JP2004238309A patent/JP2004339239A/ja active Pending
-
2005
- 2005-06-13 US US11/152,753 patent/US20050245570A1/en not_active Abandoned
-
2006
- 2006-01-26 IL IL173393A patent/IL173393A0/en unknown
- 2006-04-12 JP JP2006109338A patent/JP2006188542A/ja not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU16501A (sh) | 4-karboksiamido-2-supstituisani-1,2,3,4-tetrahidrohinolini kao inhibitori cetp | |
YU18101A (sh) | 4-amino supstituisani-2-supstituisani-1,2,3,4- tetrahidrohinolini kao inhibitori cetp | |
SE9504661D0 (sv) | New compounds | |
ES2077199T3 (es) | Nuevas piperacinas 1,4-disustituidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
ATE330585T2 (de) | Behandlung von atemerkrankungen | |
EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
MEP33708A (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor | |
HRP20050690A2 (en) | Hiv inhibiting 1,2,4-triazines | |
BR9406979A (pt) | Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal | |
RS50035B (sr) | Farmaceutska kompozicija koja sadrži fenofibrat i postupak za njeno dobijanje | |
EA200200262A1 (ru) | Пиперазиновые производные и их применение в качестве противовоспалительных агентов | |
UA44254C2 (uk) | Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція | |
AP2002002637A0 (en) | Novel piperazine | |
YU74292A (sh) | Jedinjenja za inhibiciju hiv i srodnih virusa | |
DE60120648D1 (de) | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung | |
PT99597B (pt) | Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase | |
LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
ES2147616T3 (es) | Derivados de piperidina con actividad antagonista del paf. | |
SE0102055D0 (sv) | New Compounds | |
BR9509975A (pt) | Formulação farmacêutica | |
ES2103440T3 (es) | Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
DK0904780T3 (da) | Anvendelse af farmaceutiske præparater omfattende thymol og/eller carvacrol mod histomoniasis | |
BRPI0417946A (pt) | composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto | |
SE9802209D0 (sv) | Novel compounds |